Leo Tseng

631 total citations
16 papers, 487 citations indexed

About

Leo Tseng is a scholar working on Epidemiology, Molecular Biology and Surgery. According to data from OpenAlex, Leo Tseng has authored 16 papers receiving a total of 487 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Epidemiology, 9 papers in Molecular Biology and 4 papers in Surgery. Recurrent topics in Leo Tseng's work include Fibroblast Growth Factor Research (8 papers), Liver Disease Diagnosis and Treatment (8 papers) and Pancreatitis Pathology and Treatment (4 papers). Leo Tseng is often cited by papers focused on Fibroblast Growth Factor Research (8 papers), Liver Disease Diagnosis and Treatment (8 papers) and Pancreatitis Pathology and Treatment (4 papers). Leo Tseng collaborates with scholars based in United States, Israel and France. Leo Tseng's co-authors include Rakesh Dixit, Marna Williams, Jean‐Charles Soria, David A. Tice, Steven Coats, Nai‐Shun Yao, Hank Mansbach, Cynthia L. Hartsfield, Maya Margalit and Chaoyin Chen and has published in prestigious journals such as Nature Medicine, Gastroenterology and Cancer Research.

In The Last Decade

Leo Tseng

15 papers receiving 475 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Leo Tseng United States	9	205	178	130	101	85	16	487
Alexander Meisel Switzerland	12	147 0.7×	183 1.0×	96 0.7×	30 0.3×	14 0.2×	27	486
Sarani Ghoshal United States	10	201 1.0×	115 0.6×	18 0.1×	189 1.9×	42 0.5×	15	529
Lubna Abuqayyas United States	13	255 1.2×	81 0.5×	213 1.6×	61 0.6×	18 0.2×	19	522
Anila Mehta United States	6	83 0.4×	168 0.9×	64 0.5×	44 0.4×	13 0.2×	9	392
Shifu Tang China	13	505 2.5×	215 1.2×	15 0.1×	62 0.6×	33 0.4×	25	766
Alla Verlinsky United States	7	135 0.7×	114 0.6×	31 0.2×	102 1.0×	52 0.6×	9	360
Chizuru Sogawa Japan	14	166 0.8×	119 0.7×	100 0.8×	25 0.2×	8 0.1×	20	473
Wen Peng China	14	588 2.9×	152 0.9×	15 0.1×	81 0.8×	37 0.4×	55	881
Xiaojing Jia China	13	262 1.3×	84 0.5×	24 0.2×	70 0.7×	13 0.2×	19	419

Countries citing papers authored by Leo Tseng

Since Specialization

Citations

This map shows the geographic impact of Leo Tseng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leo Tseng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leo Tseng more than expected).

Fields of papers citing papers by Leo Tseng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leo Tseng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leo Tseng. The network helps show where Leo Tseng may publish in the future.

Co-authorship network of co-authors of Leo Tseng

This figure shows the co-authorship network connecting the top 25 collaborators of Leo Tseng. A scholar is included among the top collaborators of Leo Tseng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leo Tseng. Leo Tseng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Bhatt, Deepak L., Harold Bays, Michael Miller, et al.. (2023). The FGF21 analog pegozafermin in severe hypertriglyceridemia: a randomized phase 2 trial. Nature Medicine. 29(7). 1782–1792. 66 indexed citations

Alkhouri, Naim, Donald J. Lazas, Rohit Loomba, et al.. (2023). Clinical trial: Effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy‐confirmed nonalcoholic steatohepatitis. Alimentary Pharmacology & Therapeutics. 58(10). 1005–1015. 8 indexed citations

Loomba, Rohit, Naim Alkhouri, Shibao Feng, et al.. (2023). Pegozafermin Improved Liver Histology, Liver-related Non-invasive Tests (NITs) and Metabolic Profiles in an Open-label Cohort of a Phase 1b/2a Study in Subjects with Non-alcoholic Steatohepatitis. Metabolism. 142. 155454–155454. 1 indexed citations

Rosenstock, Moti, Leo Tseng, Andrew L. Pierce, et al.. (2023). The Novel GlycoPEGylated FGF21 Analog Pegozafermin Activates Human FGF Receptors and Improves Metabolic and Liver Outcomes in Diabetic Monkeys and Healthy Human Volunteers. Journal of Pharmacology and Experimental Therapeutics. 387(2). 204–213. 16 indexed citations

Loomba, Rohit, Eric Lawitz, Juan P. Frías, et al.. (2022). Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. The Lancet. Gastroenterology & hepatology. 8(2). 120–132. 72 indexed citations

Alkhouri, Naim, Rohit Loomba, Juan P. Frías, et al.. (2022). Pegozafermin led to significant metabolic benefits, in addition to robust beneficial effects on the liver, in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH). Journal of Hepatology. 77. S732–S732. 2 indexed citations

Loomba, Rohit, Naim Alkhouri, Pierre Bédossa, et al.. (2022). Pegozafermin improved liver histology, liver-related non-invasive tests (NITs) and metabolic profiles in an open-label cohort of a Phase 1b/2a study in subjects with non-alcoholic steatohepatitis (NASH). Journal of Hepatology. 77. S730–S730. 1 indexed citations

Alkhouri, Naim, W. A. Charlton, Hank Mansbach, et al.. (2022). Pharmacokinetic (PK) and pharmacodynamics (PD) of BIO89-100, a novel glycoPEGylated FGF21, in non-alcoholic steatohepatitis (NASH) patients with compensated cirrhosis. Journal of Hepatology. 77. S727–S727.

Frías, Juan P., Grisell Ortiz‐Lasanta, Cynthia L. Hartsfield, et al.. (2022). BIO89-100 Demonstrated Robust Reductions in Liver Fat, Improved Metabolic Parameters, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH. Metabolism. 128. 155016–155016. 1 indexed citations

10.

Pechenov, Sergei, Jefferson D. Revell, Sarah Will, et al.. (2021). Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease. Scientific Reports. 11(1). 22521–22521. 55 indexed citations

11.

Frías, Juan P., Eric Lawitz, Grisell Ortiz‐Lasanta, et al.. (2021). BIO89-100 Demonstrated Robust Reductions in Liver Fat and Liver Fat Volume (LFV) by MRI-PDFF, Favorable Tolerability and Potential for Weekly (QW) or Every 2 Weeks (Q2W) Dosing in a Phase 1b/2a Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study in NASH. Journal of the Endocrine Society. 5(Supplement_1). A5–A6. 9 indexed citations

12.

Margalit, Maya, Chaoyin Chen, Leo Tseng, Moti Rosenstock, & Hank Mansbach. (2020). BIO89-100, a GlycoPEGylated FGF21 Analog, Improved Serum Lipids and Extended Half-Life in a Controlled Single Ascending Dose Trial in Healthy Subjects†. Journal of clinical lipidology. 14(4). 585–586. 4 indexed citations

13.

Coats, Steven, Marna Williams, Rakesh Dixit, et al.. (2019). Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index. Clinical Cancer Research. 25(18). 5441–5448. 222 indexed citations

14.

Mallory, Raburn M., Omar Ali, Therese Takas, et al.. (2017). A phase 1 study to evaluate the safety and pharmacokinetics of MEDI8852, an anti-influenza A monoclonal antibody, in healthy adult volunteers. Biologicals. 50. 81–86. 18 indexed citations

15.

Gupta, Shilpa, Juneko E. Grilley‐Olson, David S. Hong, et al.. (2017). Abstract CT091: Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors. Cancer Research. 77(13_Supplement). CT091–CT091. 11 indexed citations

16.

Keith, James C., Leo Albert, Leo Tseng, et al.. (2000). Oral delivery of recombinant human interleukin-11 decreases clinical signs and histologic lesions in animal models of inflammatory bowel disease. Gastroenterology. 118(4). A701–A701. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact